论文部分内容阅读
目的 观察5%咪喹莫特乳膏治疗传染性软疣的临床疗效及安全性。方法 选取2014年5~10月门诊确诊的传染性软疣患者90例,随机分为治疗组和对照组各45例。治疗组予5%咪喹莫特乳膏治疗,对照组予重组人干扰素α-2b乳膏治疗并加用他扎罗汀凝胶。2组治疗期间均每周复诊1次,连续观察4周,疗程结束时判定疗效。结果 治疗组第1、2、3、4周有效率均优于对照组,差异有统计学意义(P<0.05)。结论 5%咪喹莫特乳膏治疗传染性软疣,疗效确切,不良反应小,安全性高,值得临床推广应用。
Objective To observe the clinical efficacy and safety of 5% imiquimod cream in the treatment of molluscum contagiosum. Methods Ninety patients with molluscum contagiosum diagnosed from May to October in 2014 were randomly divided into treatment group (n = 45) and control group (n = 45). The treatment group was treated with 5% imiquimod cream, the control group was treated with recombinant human interferon alpha-2b cream and tazarotene gel was added. During the treatment period, the patients in the two groups were referred to the clinic once a week for 4 weeks, and the curative effect was judged at the end of the course of treatment. Results The effective rate of the 1st, 2nd, 3rd, 4th week of the treatment group was better than that of the control group, with statistical significance (P <0.05). Conclusion 5% imiquimod cream for the treatment of molluscum contagiosum, curative effect is accurate, the adverse reaction is small, high safety, it is worth clinical application.